Target: HIST1H2BB (H2B clustered histone 3, Gene ID: HIST1H2BB), a variant of histone H2B critical for DNA compaction and transcriptional regulation .
Immunogen: A synthetic peptide corresponding to residues around lysine 16 (K16) of human histone H2B type 1-B .
Reactivity: Confirmed for Homo sapiens (human) and Mus musculus (mouse) .
Host: Rabbit-derived IgG .
Applications: Validated for chromatin immunoprecipitation (ChIP), Western blot (WB), immunofluorescence (IF), ELISA, and immunoprecipitation (IP) .
Demonstrated efficacy in ChIP assays using HeLa cells, with immunoprecipitated DNA quantified via real-time PCR targeting the β-globin promoter .
Validated for detecting histone H2B modifications in epigenetic studies .
Detects a ~14 kDa band in human cell lines (e.g., HeLa, Jurkat) and mouse tissues (brain, liver, kidney) .
Recommended dilution range: 1:200–1:5,000 depending on sample type .
| Application | Sample Type | Result | Citation |
|---|---|---|---|
| WB | HeLa cell lysate | Clear 14 kDa band | |
| ChIP | HeLa chromatin | Enrichment of β-globin promoter DNA vs. control IgG | |
| IF | HeLa cells | Nuclear staining pattern |
Epigenetic Regulation: HIST1H2BB is part of the nucleosome core, influencing DNA accessibility for transcription and repair . Post-translational modifications (e.g., acetylation, ubiquitination) at K16 may modulate chromatin dynamics .
Disease Relevance: Antibodies targeting histone H2B isoforms are used to study aberrant epigenetic states in cancer and immune disorders .
Histone H2B is a core component of the nucleosome, a fundamental structural unit of chromatin. Nucleosomes package and compact DNA, thereby regulating access to the cellular machinery that requires DNA as a template. Histones, therefore, play a crucial role in transcriptional regulation, DNA repair, DNA replication, and overall chromosomal stability. The accessibility of DNA is modulated through a complex interplay of post-translational histone modifications, often referred to as the histone code, and dynamic nucleosome remodeling.
Further research highlights key functional aspects of histone H2B:
HIST1H2BB (Histone Cluster 1, H2bb) is a core histone protein that forms part of the nucleosome structure in human cells. As a component of chromatin, it plays crucial roles in DNA packaging, gene regulation, and epigenetic modification. The significance of HIST1H2BB in epigenetic research stems from its post-translational modifications (PTMs), particularly acetylation at specific lysine residues (including Lys5, Lys16, and Lys20), which influence chromatin structure and accessibility . Research focusing on HIST1H2BB contributes to our understanding of gene expression regulation, DNA damage response, and cellular differentiation mechanisms. Antibodies against HIST1H2BB and its modified forms serve as essential tools for investigating these biological processes.
HIST1H2BB antibodies differ primarily in their epitope recognition, host species, clonality, and conjugation status. The most significant distinctions relate to their binding specificity:
| Antibody Type | Epitope Recognition | Host | Clonality | Recommended Applications |
|---|---|---|---|---|
| HIST1H2BB (AA 2-126) | Full-length protein (AA 2-126) | Rabbit | Polyclonal | ELISA, IF, WB, IHC |
| HIST1H2BB (acLys5) | Acetylated Lysine 5 | Rabbit | Polyclonal | ELISA, IF, ICC, ChIP |
| HIST1H2BB (acLys16) | Acetylated Lysine 16 | Rabbit | Polyclonal | ELISA, IF, ICC, ChIP |
| HIST1H2BB (acLys20) | Acetylated Lysine 20 | Rabbit | Monoclonal | ELISA, IF, WB, ICC, FACS |
| HIST1H2BB (Ser14) | Phosphorylated Serine 14 | Rabbit | Polyclonal | ELISA, WB |
The Ab-16 antibody specifically recognizes the acetylated Lysine 16 residue, making it particularly valuable for studying this epigenetic modification . This distinction is crucial when designing experiments targeting specific post-translational modifications of histone H2B.
The HIST1H2BB (Ab-16) antibody demonstrates high specificity for the acetylated Lysine 16 residue of histone H2B. This specificity is critical because Lys16 acetylation is associated with transcriptionally active chromatin regions. Unlike antibodies targeting other histone variants or modifications, the Ab-16 antibody allows researchers to specifically examine this particular epigenetic mark .
For optimal western blotting results with HIST1H2BB (Ab-16) antibody, the following methodology is recommended:
Sample Preparation:
Prepare cell lysates using a cell lysis buffer supplemented with protease inhibitors and phosphatase inhibitors to preserve protein modifications .
For histone-specific applications, consider acid extraction methods to enrich for histones.
Use 15-20 μg of total cell lysate per lane for standard western blots .
Gel Electrophoresis and Transfer:
Blocking and Antibody Incubation:
Detection and Quantification:
Including appropriate controls (such as total H2B and other loading controls) is essential for accurate interpretation of results.
ChIP assays using HIST1H2BB (Ab-16) antibody require careful optimization for successful outcomes:
Cross-linking and Chromatin Preparation:
Cross-link cells with 1% formaldehyde for 10 minutes at room temperature.
Quench with 125 mM glycine for 5 minutes.
Lyse cells and sonicate to generate DNA fragments of 200-500 bp.
Confirm fragmentation efficiency by agarose gel electrophoresis.
Immunoprecipitation:
Pre-clear chromatin with protein A/G beads.
Incubate pre-cleared chromatin with HIST1H2BB (Ab-16) antibody (4-5 μg per ChIP reaction) overnight at 4°C.
Add protein A/G beads and incubate for 2-3 hours at 4°C.
Perform stringent washing steps to reduce background.
DNA Recovery and Analysis:
Reverse cross-links and purify DNA.
Analyze DNA by qPCR, sequencing, or microarray.
When comparing acetylated Lys16 distribution with other histone modifications, consistent chromatin preparation and IP conditions are essential. Sequential ChIP (Re-ChIP) can be performed to investigate co-occurrence of H2B Lys16 acetylation with other epigenetic marks.
For optimal immunofluorescence results with HIST1H2BB (Ab-16) antibody:
Sample Preparation:
Blocking and Antibody Incubation:
Block with PBS containing 0.1% TritonX-100 and 1% BSA to reduce non-specific binding .
Incubate with HIST1H2BB (Ab-16) antibody at an optimized dilution (typically 1:100-1:500) overnight at 4°C .
Use appropriate fluorophore-conjugated secondary antibodies (e.g., AlexaFluor® conjugates at 1:500 dilution) .
Imaging and Analysis:
For co-localization studies with other nuclear proteins or histone marks, sequential staining protocols may be necessary to avoid cross-reactivity between antibodies.
Accurate interpretation of HIST1H2BB Lys16 acetylation changes requires:
Changes in H2B Lys16 acetylation should be interpreted within the broader epigenetic landscape, as this modification often operates in concert with other histone marks and chromatin regulators.
Several pitfalls may affect HIST1H2BB acetylation data analysis:
Antibody Cross-Reactivity:
Pitfall: Ab-16 antibody may cross-react with similar acetylation sites on other histones.
Solution: Validate antibody specificity using peptide competition assays and knockout/knockdown controls.
Cell Cycle Effects:
Pitfall: Histone acetylation patterns change during cell cycle progression, confounding experimental results.
Solution: Synchronize cells or account for cell cycle distribution in heterogeneous populations through appropriate controls or single-cell analysis.
Sample Preparation Variability:
Pitfall: Inconsistent sample preparation can affect detection of acetylation marks.
Solution: Standardize preparation protocols and include internal controls for sample processing efficiency.
Quantification Challenges:
Pitfall: Non-linear signal response in western blots or immunofluorescence.
Solution: Establish signal linearity range for quantification and use appropriate imaging systems and analysis software.
Biological Interpretation:
Pitfall: Correlating acetylation changes with functional outcomes without causative evidence.
Solution: Complement correlative studies with functional experiments (e.g., site-specific mutation or targeted deacetylation approaches).
Careful experimental design, appropriate controls, and validation of key findings using multiple approaches can minimize these pitfalls.
When encountering weak or inconsistent signals with HIST1H2BB (Ab-16) antibody, consider these troubleshooting approaches:
For Western Blotting:
Increase antibody concentration or incubation time.
Enhance antigen retrieval by optimizing lysis conditions or using histone extraction protocols.
Reduce membrane blocking time or change blocking reagent.
Use signal enhancement systems compatible with your detection method.
Ensure proteins are adequately transferred to the membrane (especially important for small histone proteins).
For Immunofluorescence:
Optimize fixation and permeabilization conditions to improve nuclear antigen accessibility.
Increase antibody concentration or incubation time.
Consider antigen retrieval methods (such as citrate buffer treatment).
Reduce background by adjusting blocking conditions or washing stringency.
Use high-sensitivity detection systems and appropriate microscopy settings.
For ChIP Assays:
Increase antibody amount or chromatin incubation time.
Optimize chromatin fragmentation conditions.
Reduce stringency of wash conditions.
Use carrier proteins or sonicated salmon sperm DNA to reduce non-specific binding.
Optimize PCR conditions for target regions.
For all applications, compare different antibody lots and consider testing alternative antibodies targeting the same epitope from different suppliers.
Validating HIST1H2BB (Ab-16) antibody specificity is critical for reliable results:
Peptide Competition Assays:
Pre-incubate antibody with varying concentrations of a synthetic peptide containing acetylated Lys16.
Compare signal with and without peptide competition to confirm specificity.
Include non-acetylated peptide controls to verify modification specificity.
Genetic Approaches:
Use cells with HIST1H2BB knockdown/knockout as negative controls.
If possible, use Lys16-to-Arg mutants (mimicking non-acetylatable state) to verify specificity.
Enzymatic Manipulation:
Treat samples with histone deacetylases (HDACs) to remove acetylation marks and confirm signal reduction.
Conversely, treat with HDAC inhibitors to increase acetylation and enhance signal.
Mass Spectrometry Correlation:
Compare antibody-based detection with mass spectrometry quantification of Lys16 acetylation levels.
This provides orthogonal validation of antibody specificity and sensitivity.
Cross-Reactivity Testing:
Test reactivity against other acetylated lysines on H2B and other histones.
Include synthetic peptide arrays containing various histone modifications to determine cross-reactivity profiles.
Thorough validation ensures confidence in experimental outcomes and should be performed for each new lot of antibody.
Integrating HIST1H2BB (Ab-16) antibody into multi-omics approaches can provide comprehensive insights into epigenetic regulation:
ChIP-seq + RNA-seq Integration:
Perform ChIP-seq using HIST1H2BB (Ab-16) antibody to map Lys16 acetylation genome-wide.
Combine with RNA-seq from matched samples to correlate acetylation patterns with transcriptional output.
Use computational approaches to identify direct regulatory relationships between acetylation and gene expression.
Sequential ChIP (Re-ChIP) Applications:
Implement Re-ChIP protocols to investigate co-occurrence of H2B Lys16 acetylation with other histone modifications or chromatin-associated proteins.
This approach reveals combinatorial epigenetic states associated with specific functional outcomes.
CUT&RUN or CUT&Tag Adaptations:
Adapt HIST1H2BB (Ab-16) antibody for use in cutting-edge technologies like CUT&RUN or CUT&Tag.
These techniques offer higher signal-to-noise ratios and require less input material than traditional ChIP.
Single-Cell Applications:
Optimize protocols for single-cell ChIP-seq or CUT&Tag to investigate cell-to-cell heterogeneity in Lys16 acetylation patterns.
Integrate with single-cell RNA-seq or ATAC-seq data for comprehensive epigenomic profiling at single-cell resolution.
Spatial Omics Integration:
Combine immunofluorescence using HIST1H2BB (Ab-16) antibody with spatial transcriptomics approaches to correlate acetylation patterns with gene expression in a spatial context.
These integrative approaches provide a more comprehensive understanding of how H2B Lys16 acetylation contributes to gene regulation in different biological contexts.
HIST1H2BB (Ab-16) antibody has emerging applications in disease-related research:
Cancer Epigenetics:
Map alterations in H2B Lys16 acetylation patterns across cancer types to identify epigenetic signatures associated with malignancy.
Correlate acetylation changes with mutations in histone acetyltransferases or deacetylases that target H2B.
Investigate the impact of oncogenic signaling pathways on H2B Lys16 acetylation dynamics.
Neurodegenerative Disorders:
Examine how H2B Lys16 acetylation patterns change during neurodegeneration.
Investigate the relationship between acetylation changes and transcriptional dysregulation in affected neurons.
Study the impact of therapeutic compounds on restoring normal acetylation patterns.
Developmental Disorders:
Track H2B Lys16 acetylation during normal and abnormal development to identify critical regulatory events.
Investigate how mutations in epigenetic regulators affect H2B acetylation and subsequent developmental outcomes.
Immunological Research:
Study how H2B Lys16 acetylation regulates immune cell differentiation and function.
Investigate epigenetic reprogramming during immune responses and how this relates to autoimmune conditions.
Drug Discovery Applications:
Use HIST1H2BB (Ab-16) antibody to screen compounds for their ability to modulate H2B Lys16 acetylation.
Develop ChIP-seq-based screening platforms to identify epigenetic modulators with therapeutic potential.
These applications highlight the importance of H2B Lys16 acetylation in diverse pathological contexts and its potential as a therapeutic target.
For challenging samples or limited material, consider these optimized approaches:
Micro-ChIP Protocols:
Adapt standard ChIP protocols for low cell numbers (1,000-10,000 cells).
Add carrier proteins or DNA to prevent loss during precipitation steps.
Use high-sensitivity detection methods for ChIP-qPCR analysis.
Consider tagmentation-based approaches (ChIPmentation) to generate libraries from limited material.
Fixed Tissue Samples:
For FFPE (formalin-fixed paraffin-embedded) samples, implement optimized antigen retrieval procedures.
Consider longer antibody incubation times (24-48 hours) at lower temperatures.
Use signal amplification systems for immunohistochemistry applications.
Single-Cell Applications:
Optimize fixation conditions to preserve nuclear architecture while enabling antibody penetration.
Implement tyramide signal amplification for immunofluorescence detection.
For droplet-based single-cell approaches, carefully optimize antibody concentration and incubation conditions.
Primary Cell Cultures:
Adjust lysis conditions to account for different nuclear properties compared to established cell lines.
Consider native ChIP approaches (without crosslinking) for sensitive primary cells.
Implement gentle handling procedures to minimize stress-induced epigenetic changes.
Non-mammalian Model Systems:
Validate antibody cross-reactivity with the species of interest.
Optimize extraction and immunoprecipitation conditions for different chromatin structures.
These optimizations expand the utility of HIST1H2BB (Ab-16) antibody to diverse experimental contexts and sample types, enabling broader research applications.
The integration of HIST1H2BB (Ab-16) antibody with emerging technologies offers exciting research possibilities:
CRISPR-Based Epigenome Editing:
Use HIST1H2BB (Ab-16) antibody to validate the specificity and efficiency of CRISPR-based acetylation editors targeting H2B Lys16.
Monitor acetylation changes following targeted recruitment of histone acetyltransferases or deacetylases to specific genomic loci.
Liquid Chromatin Approaches:
Implement HIST1H2BB (Ab-16) antibody in liquid chromatin immunoprecipitation techniques that offer improved sensitivity and reproducibility.
These approaches enable profiling of H2B Lys16 acetylation with smaller sample inputs and reduced background.
Live-Cell Imaging:
Develop intracellular antibody fragments or nanobodies based on HIST1H2BB (Ab-16) for live-cell imaging of acetylation dynamics.
Combine with optogenetic tools to study real-time changes in acetylation following controlled perturbations.
High-Throughput Screening:
Adapt HIST1H2BB (Ab-16) antibody for use in automated high-content screening platforms to identify compounds or genetic factors that modulate H2B Lys16 acetylation.
Develop scalable assays for drug discovery applications targeting epigenetic regulators.
These applications represent the frontier of epigenetic research, leveraging HIST1H2BB (Ab-16) antibody to address complex questions about chromatin regulation and function.